Cytokine fusion protein treatment.
Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.
Schrama
David
D
Department of Dermatology, Julius Maximilians University, Würzburg, Germany.
Straten
Per thor
Pt
Bröcker
Eva-Bettina
EB
Reisfeld
Ralph A
RA
Becker
Jürgen C
JC
D000818:Animals; D002999:Clone Cells; D016207:Cytokines / Q000627:therapeutic use*; D008233:Lymphotoxin-alpha / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013601:T-Lymphocytes / Q000276:immunology; D014407:Tumor Cells, Cultured
D016207:Cytokines; D008233:Lymphotoxin-alpha; D011993:Recombinant Fusion Proteins